Hepatology
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into the global hepatology drug market. Track R&D, regulatory approvals, and investment opportunities in liver disease therapeutics.
Showing 1–7 of 7 articles
Quick answer
NovaPharmaNews Hepatology hub for FDA covers 7 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Gilead Secures First Hepatitis D Drug Approval, Sparking Bay Area Competition
Inventiva Bolsters Executive Team Ahead of Lanifibranor Phase 3 Data
Gilead's Hepcludex Secures FDA Approval: Implications for Pharma
CRISPR Therapeutics' CASGEVY Reaches 60,000+ Eligible Patients Across 10 Countries Following Global Approvals
IPEC Excipient World Biologics Summit 2026: Recap
Novo Nordisk's Denecimig Shows Significant Bleeding Reduction in Hemophilia A Phase 3 Trial Published in NEJM
Expression Therapeutics Receives FDA Fast Track and Rare Pediatric Disease Designations for Hemophilia A Stem Cell Therapy
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.